HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients
HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients
复制标题
DOI：
10.1097/00002030-199910220-00002
复制
发表时间：
1999-10-22
期刊：
影响因子：
3.8
通讯作者：
Yarchoan, R
中科院分区：
文献类型：
--
作者：
Pinto, LA;Berzofsky, JA;Yarchoan, R
目的：评价HIV合成肽疫苗在HIV血清阳性人群中的安全性和免疫原性。免疫原为PCLUS3-18MN和PCLUS6.1-18MN。方法：8例HIV感染者按Montanide ISA 51进行6次皮下注射160 mU PCLUS3-18MN，第一次免疫后纵向随访1年。检测外周血单核细胞(PBMC)特异性T辅助细胞和细胞毒性T细胞(CTL)反应、HIV-1(MN)中和抗体和抗HIV PCLUS 3和P18 MN多肽抗体。结果：PCLUS 3-18MN免疫后36周，PCLUS 3-18MN特异性T细胞应答显著增加(P<；0.05，经多重比较调整后)。一名患者在免疫后观察到P18MN特异性CTL反应，该反应在接种前不存在。在免疫前滴度较低的三名患者中，血清HIV-1(MN)中和抗体滴度均升高。在研究期间，血浆HIV RNA水平和CD4细胞计数没有明显变化。结论：这两种多肽都可以安全地用于HIV感染者，PCLU3-18MN诱导HIV多肽特异性免疫应答增加。(C)1999年，Lippincott Williams&Wilkins。
Objective: A phase I trial was conducted to evaluate the safety and immunogenicity of an HIV synthetic peptide vaccine in HIV-seropositive individuals. The immunogens used in this study were PCLUS 3-18MN and PCLUS 6.1-18MN envelope peptides.Methods: Eight HIV-infected patients received six subcutaneous injections of 160 mu g PCLUS 3-18MN in Montanide ISA 51 and were followed longitudinally for a year after the first immunization. Peripheral blood mononuclear cells (PBMC) were tested for peptide-specific T helper and cytotoxic T cell (CTL) responses, HIV-1(MN) neutralizing antibodies and antibodies against HIV PCLUS 3 and P18 MN peptides.Results: PCLUS 3-18MN-specific T helper responses were significantly increased at 36 weeks (P < 0.05, after adjustment for multiple comparisons) following initial immunization with PCLUS 3-18MN. A P18MN-specific CTL response, not present prior to vaccination, was observed after immunization in one patient. Serum HIV-1(MN)-neutralizing antibody titers increased in each of the three patients who had low titers prior to immunization. Plasma HIV RNA levels and CD4 cell counts did not change appreciably during the study period.Conclusions: This trial demonstrates that both peptides can be safely administered to HIV-infected individuals and that PCLUS 3-18MN induces increases in HIV peptide-specific immune responses. (C) 1999 Lippincott Williams & Wilkins.